These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 1554717)

  • 21. 1H NMR structural characterization of a recombinant kringle 2 domain from human tissue-type plasminogen activator.
    Byeon IJ; Kelley RF; Llinás M
    Biochemistry; 1989 Nov; 28(24):9350-60. PubMed ID: 2558718
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Solution structure of the tissue-type plasminogen activator kringle 2 domain complexed to 6-aminohexanoic acid an antifibrinolytic drug.
    Byeon IJ; Llinás M
    J Mol Biol; 1991 Dec; 222(4):1035-51. PubMed ID: 1762144
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Identification of two functionally distinct lysine-binding sites in kringle 37 and in kringles 32-36 of human apolipoprotein(a).
    Ernst A; Helmhold M; Brunner C; Pethö-Schramm A; Armstrong VW; Müller HJ
    J Biol Chem; 1995 Mar; 270(11):6227-34. PubMed ID: 7890760
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evidence that the conformation of unliganded human plasminogen is maintained via an intramolecular interaction between the lysine-binding site of kringle 5 and the N-terminal peptide.
    Cockell CS; Marshall JM; Dawson KM; Cederholm-Williams SA; Ponting CP
    Biochem J; 1998 Jul; 333 ( Pt 1)(Pt 1):99-105. PubMed ID: 9639568
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Crystal structures of the recombinant kringle 1 domain of human plasminogen in complexes with the ligands epsilon-aminocaproic acid and trans-4-(aminomethyl)cyclohexane-1-carboxylic Acid.
    Mathews II; Vanderhoff-Hanaver P; Castellino FJ; Tulinsky A
    Biochemistry; 1996 Feb; 35(8):2567-76. PubMed ID: 8611560
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The construction and expression of chimeric urokinase-type plasminogen activator genes containing kringle domains of human plasminogen.
    Boutaud A; Castellino FJ
    Arch Biochem Biophys; 1993 Jun; 303(2):222-30. PubMed ID: 8512311
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Complete assignment of the aromatic proton magnetic resonance spectrum of the kringle 1 domain from human plasminogen: structure of the ligand-binding site.
    Motta A; Laursen RA; Llinás M; Tulinsky A; Park CH
    Biochemistry; 1987 Jun; 26(13):3827-36. PubMed ID: 2820478
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Expression, purification and characterization of the recombinant kringle 2 and kringle 3 domains of human plasminogen and analysis of their binding affinity for omega-aminocarboxylic acids.
    Marti D; Schaller J; Ochensberger B; Rickli EE
    Eur J Biochem; 1994 Jan; 219(1-2):455-62. PubMed ID: 8307012
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Roles of individual kringle domains in the functioning of positive and negative effectors of human plasminogen activation.
    Menhart N; Hoover GJ; McCance SG; Castellino FJ
    Biochemistry; 1995 Feb; 34(5):1482-8. PubMed ID: 7849007
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Functional properties of the recombinant kringle-2 domain of tissue plasminogen activator produced in Escherichia coli.
    Wilhelm OG; Jaskunas SR; Vlahos CJ; Bang NU
    J Biol Chem; 1990 Aug; 265(24):14606-11. PubMed ID: 2117612
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Synthesis and expression of a gene from kringle-2 domain of tissue plasminogen activator in E. coli.
    Hua ZC; Fu HL; Chen YH; Yu RR; Wang J; Zhu DX
    Sci China B; 1994 Jun; 37(6):667-76. PubMed ID: 7917003
    [TBL] [Abstract][Full Text] [Related]  

  • 32. On the interaction of the finger and the kringle-2 domain of tissue-type plasminogen activator with fibrin. Inhibition of kringle-2 binding to fibrin by epsilon-amino caproic acid.
    van Zonneveld AJ; Veerman H; Pannekoek H
    J Biol Chem; 1986 Oct; 261(30):14214-8. PubMed ID: 3021732
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Purification and characterization of tissue plasminogen activator kringle-2 domain expressed in Escherichia coli.
    Cleary S; Mulkerrin MG; Kelley RF
    Biochemistry; 1989 Feb; 28(4):1884-91. PubMed ID: 2497771
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tissue-type plasminogen activator domain-deletion mutant BM 06.022: modular stability, inhibitor binding, and activation cleavage.
    Hu CK; Kohnert U; Wilhelm O; Fischer S; Llinás M
    Biochemistry; 1994 Oct; 33(39):11760-6. PubMed ID: 7918392
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Thermodynamic properties of the binding of alpha-, omega-amino acids to the isolated kringle 4 region of human plasminogen as determined by high sensitivity titration calorimetry.
    Sehl LC; Castellino FJ
    J Biol Chem; 1990 Apr; 265(10):5482-6. PubMed ID: 2108141
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Solution structure of the epsilon-aminohexanoic acid complex of human plasminogen kringle 1.
    Rejante MR; Llinás M
    Eur J Biochem; 1994 May; 221(3):939-49. PubMed ID: 8181476
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Structure and ligand binding determinants of the recombinant kringle 5 domain of human plasminogen.
    Chang Y; Mochalkin I; McCance SG; Cheng B; Tulinsky A; Castellino FJ
    Biochemistry; 1998 Mar; 37(10):3258-71. PubMed ID: 9521645
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Kringle solution structures via NMR: two-dimensional 1H-NMR analysis of horse plasminogen kringle 4.
    Cox M; Schaller J; Boelens R; Kaptein R; Rickli E; Llinás M
    Chem Phys Lipids; 1994 Jan; 67-68():43-58. PubMed ID: 8187244
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Human plasminogen kringle 3: solution structure, functional insights, phylogenetic landscape.
    Christen MT; Frank P; Schaller J; Llinás M
    Biochemistry; 2010 Aug; 49(33):7131-50. PubMed ID: 20617841
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Protein-ligand interactions in the lysine-binding site of plasminogen kringle 4 are different in crystal and solution. Electrostatic interactions studied by site-directed mutagenesis exclude Lys35 as an important acceptor in solution.
    Nielsen PR; Einer-Jensen K; Holtet TL; Andersen BD; Poulsen FM; Thøgersen HC
    Biochemistry; 1993 Dec; 32(48):13019-25. PubMed ID: 8241155
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.